Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data

Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications

Guruprasad P. Aithal, Christopher P. Day, Patrick Kesteven et al. · The Lancet · 1999 · 1.2K citations

Medicine, Pharmacokinetics, Pharmacology +12

Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions

Allan E. Rettie, Kenneth R. Korzekwa, Kent L. Kunze et al. · Chemical Research in Toxicology · 1992 · 602 citations

Medicine, Pharmacology, Toxicology +17

The role of the CFP2C9-Leu 359 allelic variant in the tolbutamide polymorphism

Theresa H. Sullivan-Klose, Burhan I. Ghanayem, Douglas A. Bell et al. · Pharmacogenetics · 1996 · 587 citations

Medicine, Genetics, Pharmacology +17

Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9

Allan E. Rettie, Larry C. Wienkers, Frank J. Gonzalez et al. · Pharmacogenetics · 1994 · 493 citations

Medicine, Molecular Genetics, Pharmacology +10

Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the Hepatic Uptake of Pitavastatin in Humans

Masaru Hirano, Kazuya Maeda, Yoshihisa Shitara et al. · Journal of Pharmacology and Experimental Therapeutics · 2004 · 442 citations

Pharmacy, Biochemistry, Pharmacology +16